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ABSTRACT
TUBULAR CARCINOMA OF THE BREAST VERSUS INVASIVE DUCTAL CARCINOMA TREATED
WITH BREAST CONSERVATION THERAPY
Gene-Fu F. Liu, Qifeng Yang, Bruce G. Haffty,, Meena S. Moran.
Department of Therapeutic Radiology, Yale University, School of Medicine, New Haven, CT.

Purpose: The purpose of our study is to evaluate our institutional experience of treating Tubular
Carcinoma of the Breast (TC) and Invasive Ductal Carcinoma (IDC) with Breast Conservation
Therapy (BCT), consisting of conservative surgery (CS) and radiation therapy (RT), and to
compare clinical-pathologic features and long-term outcomes.
Materials and Methods: A review of our institution’s tumor registry from 1975-2007 was
performed, followed by a central pathology review of available slides, yielding 71 cases of Stage
I/II TC and 2238 cases of Stage I/II IDC treated with BCT.
Results: Clinical-pathologic features and outcomes were then analyzed by subtype to detect
significant differences. The median follow-up was 7 years. The TC cohort presented more
frequently with pT1 disease (97% vs. 80%, p=0.0007), pN0 disease (95% vs. 74%, p=0.0004),
hormone-receptor positivity (ER+: 89% vs. 62%, p=0.0001; PR+: 81% vs. 52%, p=0.0001), and
HER-2 negativity (89% vs. 71%, p= 0.04). Clinical outcomes also favored the TC cohort, with
lower rates of breast cancer-related death (1% vs. 10%; p = 0.0109) and distant metastasis (1%
vs. 13%; p = 0.0028), and higher rates of 10-year overall (90% vs. 80%; p=0.033), cause-specific
(99% vs. 86%; p=0.011), and disease-free (99% vs. 82%; p=0.003) survival. There was a nonsignificant trend towards improved breast relapse-free survival for the TC cohort (95% vs. 87%;
p=0.062) but no difference in nodal relapse-free survival or contralateral breast relapse-free
survival (all p-values > 0.05) between the cohorts.
Conclusion: Our institutional experience suggests that TC, when compared to IDC, is associated
with more favorable clinical-pathologic features and comparable, if not superior, outcomes
following BCT, suggesting the appropriateness of a conservative approach to this rare subtype.
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INTRODUCTION
Breast conservation therapy (BCT), consisting of a wide excision of the primary
breast lesion and loco-regional radiotherapy (RT), has been demonstrated in multiple
randomized trials to be equivalent to mastectomy with regards to disease-free survival
(DFS) and overall survival (OS) in the treatment of early stage breast cancer.1,2
However, these reports have not stratified patients by subtype and were mostly comprised
of patients with invasive ductal carcinoma (IDC), which constitute approximately 6879%. of invasive breast cancer histologies.3-5 Few studies have analyzed the outcomes of
BCT on less prevalent histologies of the disease. Tubular carcinoma (TC) is one such
subtype, comprising approximately only 1% of all invasive breast cancers.3,4
Table 1. Demographic characteristics of 139,310 women
diagnosed with nine different histologic types of breast cancer
Histology

n

Percent

Invasive Ductal

102,463

73.6%

Invasive Lobular

11,275

8.1%

Ductal/Lobular

9,636

6.9%

Mucinous

3,248

2.3%

Comedo

2,222

1.6%

Inflammatory

2,095

1.5%

Tubular

1,983

1.4%

Medullary

1,617

1.2%

Papillary

618

0.4%

Table taken from Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast
cancer. British J Cancer. 2005 Oct 31;93(9):1046-52.

5

Histopathology
Once termed the “well-differentiated carcinoma of the breast” or “orderly
carcinoma of the breast,”6 TC can appear merely as benign tubules on microscopic
examination. Though its histopathologic definition has evolved over time, it currently
consists of three main characteristics: 1.) Well-differentiated tubules in a stellate
infiltrating configuration, 2.) Bland epithelium with non-pleomorphic nuclei, and 3.)
Myoepithelial cells absent on immunohistochemical staining.7
The first characteristic is the presence of well-differentiated tubules, with a
stellate infiltrating configuration,7 i.e., the tubules radiate outward through normal
mammary tissue. In addition, TC characteristically incites a fibrous reaction and thus is
typically surrounded by a reactive fibrous stroma on microscopic exam.8 Though the
tubules often contain secretory material and cellular debris, they remain widely patent,
helping to differentiate TC from other lesions featuring obliterated tubules and ducts, e.g.,
sclerosing adenosis.9 Finally, the tubules are often angular in conformation, and their
pointed ends are referred to as “prows,” as they resemble the front of a ship or boat.10
The minimal percentage of tumor cells forming tubules—also known as
“tubularity”—required to diagnose a TC has evolved in the literature.

Initially,

pathologists established 90% as the minimal tubularity required. Such lesions merited the
diagnosis of a “pure” TC.

Correspondingly, lesions between 75-90% tubular histology

were labeled “mixed TC.”11 The cutoff of 75% has been established to hold clinical
significance in numerous studies, including one by Carstens et al., which reported that
patients with lesions of 50-75% tubularity shared survival outcomes similar to IDC at 20
years (p>0.998). In contrast, there was a highly significant difference in Kaplan-Meier
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survival curves between a cohort of IDC versus a cohort of mixed and pure TC cases (p
<0.001).12
Currently, however, the distinction between mixed and pure TC is considered
unnecessary, as their prognostic equivalency has been established by several studies. In
particular, a large review by Peters, et al. of 100 cases, demonstrated the association
between percent tubular histology and tumor aggressiveness.13 In the review, there was
no difference in the incidences of local recurrence, distant metastasis, or death from
breast cancer between cases of mixed and pure TC.

In contrast, patients with lesions

with less than 75 percent tubular histology suffered proportionally worse rates of the
aforementioned clinical parameters, in addition to larger mean tumor size (Table 2).
Table 2. Comparative Features of Carcinomas
of Varying Tubular Component
Percent

Percent
Mean Size

Tubular

n

Percent Distant

Percent Dead

Metastasis

of Disease

Local
(cm)

Histology

Recurrence

100

16

1.79

0

0

0

76-99

20

2.15

0

0

0

51-75

16

2.01

6

31

0

31-50

23

2.50

4

48

17

5-30

22

2.54

4

25

4

Figure taken from Peters GN, Wolff M, Haagensen CD. Tubular carcinoma of the breast.
Clinical pathologic correlations based on 100 cases. Ann Surg 1981; 193: 138-149.

Of note, the 75% cutoff does not apply to lesions of mixed tubular and cribriform
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carcinoma histology. In these cases, the diagnosis is that of the dominant histology found
in greater than 50% of the lesion because both cribriform and tubular lesions share
excellent prognoses. However, the same classification criteria does not apply to mixed
tubular and lobular lesions, as described in greater detail below.
In addition to the presence of well-defined tubules, the second diagnostic criteria
of TC is a lack of nuclear pleomorphism,14 and more than 90% of the cells must feature
nuclear grade I, as codified by various nuclear grading systems, e.g., Bloom-Richardson
or Nottingham, from grades 1 to 3.7 Grade I nuclei are devoid of condensed chromatin,
prominent nucleoli, and frequent mitotic figures, and the presence of such pleomorphism
in a TC is highly unusual; its presence should prompt a search for an alternative histologic
diagnosis. In addition to low-grade nuclei, the tumor cells themselves are also welldifferentiated, being uniform in conformation, either normal or moderately enlarged in
size, and arranged in a single epithelial layer.7
However, the presence of tubules and a single-layer of bland epithelium are not
pathognomonic findings.

Indeed, the aforementioned description also depicts the

histology belonging to normal breast tissue or benign sclerosing lesions, such as
sclerosing adenosis.15 At this juncture in the differential diagnosis, the delimiting factor is
the third characteristic of a TC: the presence or absence of a myoepithelial cell layer, the
lack of which is a feature shared amongst all invasive breast cancers. Myoepthelial cells
are detected via immunohistochemical staining against a variety of markers (Table 3) and
their absence confirms the invasive nature of a lesion. Their presence supports an in situ
process.7
Table 3. Immunohistologic Markers of Myoepithelial Cells
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Marker

Sensitivity

Specificity

Calponin

Excellent

Very good

p63

Excellent

Excellent

Smooth muscle myosin heavy

Good

Excellent

CD10 (CALLA)

Good

Good

High molecular weight

Very good

Poor

Maspin

Good

Poor

S100

Good

Very poor

Actin

Good

Very poor

chain

cytokeratin

Table from Kempson R. Stanford School of Medicine Surgical Pathology Criteria: Tubular
carcinoma of the breast. <Available at: http://surgpathcriteria.stanford.edu/breast/tubularcabr>.
Accessed, 2008.

Associated Lesions
TC is frequently associated with foci of ductal carcinoma in situ (DCIS).

Historically, the relationship between the lesions was cited so often in the literature
(Table 4) that many postulated that TC was an intermediate histology between DCIS and
IDC.
Table 4. Frequency of Associated Intraductal Disease
Observed in Tubular Carcinoma
Study

No. of Patients

No. with DCIS (%)

Deos6

145

99 (68%)

9

Winchester16

50

16 (32%)

Cabral17

44

23 (52%)

Oberman18

25

21 (84%)

McBoyle19

22

14 (64%)

Total

286

173 (60%)

Abbreviations: DCIS = ductal carcinoma in situ

Differential Diagnosis
The well-differentiated histopathology of TC dictates that lesions graded as II or
III in overall histology (by various grading systems) are not tubular by definition.7 As
another consequence of its appearance, TC can be readily misclassified as benign lesions,
e.g., sclerosing adenosis, microglandular adenosis, tubular adenosis, radial scar, and thus
demands adequate tissue examination when its diagnosis is suspected. At a minimum, a
core-needle biopsy is required, as examination with fine-needle aspiration cytology is
associated with a high false negative rate.20,21
Even with adequate tissue, however, differentiating TC from other lesions can be
difficult. One such challenge is the important distinction between TC, an invasive breast
cancer, and sclerosing adenosis, a benign subtype of mammary hyperplasia, as both
growths feature tubular formation and benign appearing epithelium. The comparative
ultrastructure only has subtle, non-specific differences (Table 5). TCs feature tubules
with a stellate, infiltrating pattern, patent ducts, minimal branching, and a single layer of
cells. In contrast, sclerosing adenosis has tubules with a circumscribed and nodular
pattern, obliterated lumens, frequent branching, and occasional regions of multi-layered
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epithelium.

As stated above, the crucial difference is the presence or absence of

myoepithelium as detected by immunohistochemistry.
Table 5. Comparative Ultrastructure of Tubular Carcinoma
Versus Sclerosing Adenosis
Tubular Carcinoma

Sclerosing Adenosis

Stellate infiltrating pattern

Circumscribed, nodular

Patent ducts, gaping lumens

Occasional obliterated ducts

Minimal branching

Frequent branching

Single layer of cells

Occasional multi-layered epithelium

Table from Kempson R. Stanford School of Medicine Surgical Pathology Criteria: Tubular
carcinoma of the breast. <Available at: http://surgpathcriteria.stanford.edu/breast/tubularcabr>.
Accessed, 2008.

Another important distinction is differentiating TC versus tubulo-lobular
carcinoma, with the latter carrying a worse prognosis between that of tubular and
infiltrating lobular carcinoma.22 In this differential, the percentage of tumor cells
organized into tubules is the defining factor (Table 6). If greater than 90% of the lesion
features tubules, then it is termed a TC. But if greater than 10% of the lesion has lobular
carcinomatous feautures, then it is considered a tubulolobular carcinoma.

Of note,

molecular staining against E-cadherin typically yields positive findings for both lesions.23
Table 6. Comparative Ultrastructure of Tubular Carcinoma
Versus Sclerosing Adenosis
Tubular Carcinoma

Sclerosing Adenosis

90% pure tubular pattern

Mixed tubular and lobular patterns
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Stellate infiltrating architecture

Linear

infiltrative

pattern,

frequently

concentric
Table from Kempson R. Stanford School of Medicine Surgical Pathology Criteria: Tubular
carcinoma of the breast. <Available at: http://surgpathcriteria.stanford.edu/breast/tubularcabr>.
Accessed, 2008.

Of less importance is the distinction between TC and a small, well-differentiated,
low-grade IDC. Though there are differences in the ultrastructure of both (Table 7), a
small, low-grade, well-differentiated infiltrating ductal carcinoma probably carries such
an excellent prognosis that the prognostic information gained in such a distinction is
minimal.7
Table 7. Comparative Ultrastructure of Tubular Carcinoma
Versus Grade I Infiltrating Ductal Carcinoma
Tubular Carcinoma

Grade I Infiltrating Ductal Carcinoma, NOS

Stellate infiltration

Irregular infiltration

90% tubules

May have >10% ribbons or cords

Infrequent branching

Frequent budding and branching

Single layer of cells

May show stratification

Uniform chromatin

Slightly irregular chromatin

Nucleoli inconspicuous

Nucleoli may be prominent

Table from Kempson R. Stanford School of Medicine Surgical Pathology Criteria: Tubular
carcinoma of the breast. <Available at: http://surgpathcriteria.stanford.edu/breast/tubularcabr>.
Accessed, 2008.

Prognostic Features
Size
TC is associated with excellent prognostic features.

First, TC is smaller at
12

presentation than most breast cancer histologies, averaging only 1 cm in largest
diameter.6,11,13 A recent review of the SEER (Surveilance, Epidemiology, and End
Results) database reported that 95% of tubular carcinoma presented at a size of 2.0 cm or
less, compared with 61% of IDC, 42% of medullary carcinoma, and 57% of papillary
carcinoma.4
Its small size makes palpation exceedingly difficult and consequently the majority of
tubular carcinomas, approximately 64-84%, are detected with the aid of mammographic
screening.16,19 Of note, TC does not have any unique mammographic or sonographic
features which differentiate it from other lesions, malignant or benign,

24

and though

certain features may suggest its diagnosis, the current literature recommends that
diagnosis should be based solely on histologic examination.
Mammography is so important in the detection of TC that it may have introduced
artifact to the existing literature. For instance, though the incidence of TC has steadily
increased over the past decade (Table 8),3 it has been postulated that the increase is
merely a byproduct of increased mammographic screening.
Table 8. Number of cases of tubular carcinoma by year.
Year

Number of cases of tubular carcinoma

1992-1993

239

1994-1995

331

1996-1997

367

1998-1999

516

2000-2001

530

Table taken from Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast
cancer. British J Cancer. 2005 Oct 31;93(9):1046-52.
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This theory is bolstered by the disproportionate percentage of TC in cohorts of patients
with mammographically-detected breast cancer. One Australian study noted that TC
comprised a disproportionate 3.4% of one such cohort.25 Another possible artifact of
mammographic detection is the high rate of positive family histories of breast cancer
documented amongst patients with TC. Positive family histories were reported in 40%
(6/15) in a study by Lagios et al.26 and 33% (13 of 39) in a study by Holland et al.27
Previous authors have hypothesized that this phenomenon is not truly reflective of the
hereditability of TC.26 Rather, it is argued that patients with TC often have positive
family histories because those with a family history of breast cancer may be more
motivated to comply with rigorous mammographic screening and are thus more apt to
detect smaller lesions. Nevertheless, other studies have challenged the very notion of an
increased hereditary component of TC. Specifically, Claus et al, in a study defining a
family history to include only first-degree relatives, found TC to have the least
association with positive family histories among six histologic breast cancer subtypes.28
Furthermore, Burki et al. reported that there was no stastical difference in the relative risk
of breast cancer between first-degree relatives of patients with tubular, invasive ductal, or
medullary carcinoma.29

Regional Lymph Node Involvement
In early-stage disease, the regional lymph node status, as determined by axillary
or sentinel node dissection, is the single most important prognostic factor,30 and patients
with TC often have negative nodes. The SEER review cited above reported that cases of
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TC had positive lymph nodes only 7% of the time, compared with 33% of IDC, 29% of
medullary carcinoma, and 22% of papillary carcinoma.4

Predictive Features
Predictive features predict response to treatment. In breast cancer, the predictive
features which most influence management are estrogen receptor (ER), progesterone
receptor (PR), and HER-2 status.

Hormone Receptor Status
Patients with cancers expressing ER or PR are candidates for endocrine
modulating therapy to prevent estrogen-mediated growth stimulation of cancer cells.
Such therapy can be accomplished via different strategies in premenopausal and
postmenopausal women. In premenopausal patients, ovarian ablation, removal, or
temporary pharmacologic suppression (with gonadotropin releasing hormone analogs,
e.g., goserelin, leuprolide) are viable options. Postmenopausal patients have the option of
inhibiting estrogen production via aromatase inhibitors, such as anastrazole, letrozole, or
exemestane.

Finally, adjuvant tamoxifen, a selective estrogen receptor modulator

represents another standard option for women with hormone receptor positive tumors.
A recent review of the SEER database reported that 95% of TC are ER positive
and 81% are PR positive, thus making endocrine regulating therapy a regularly
prescribed component of TC management. In comparison, only 78% and 67% of IDC are
ER- or PR-positive, respectively.4
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HER-2 Status
The HER2 oncogene encodes for a member of the epidermal growth factor
receptor family. As a prognostic feature, HER2 over-expression is associated with higher
rates of disease recurrence and death and influences chemotherapy utilization in such
patients.31 As a predictive feature, HER2 status is predictive for resistance to systemic
therapy but also predicts response to trastuzumab or lapatinib, humanized anti-HER2
monoclonal antibodies.32 Almost all cases of TC are HER2 negative.{Oakley, 2006}

Significance of Prognostic Features
A large multi-institutional review of cases of tubular, mucinous, and IDC
compared features of breast cancer between the three histologies and found that in
addition to having a smaller size at presentation and decreased nodal positivity as
compared to IDC, TC was also more frequently associated with estrogen receptor (ER)positivity (91% vs. 82%; p = 0.001), progesterone receptor (PR)-positivity (75% vs. 61%;
p = 0.001), low S-phase fraction (89% vs. 50%;p = 0.001), and diploid DNA ploidy (81%
vs. 44%; p =0.05).
Interestingly, however, none of these traditional prognostic features influenced
clinical outcomes for cases of TC in the study. Univariate and multivariate analyses of
disease-free survival for TC (n=277, 14 events) demonstrated that neither tumor size,
nodal status, ER status, PR status, nor S-phase fraction correlated with disease-free
survival. In addition, previous small, single-institution studies of TC also suggest that
nodal spread is not associated with worse prognosis,16,33,34 making this cancer distinct
from the majority of breast cancer histologies.

One of the only features of TC
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demonstrated to correlate with a clinical parameter is lymphovascular invasion; in a
single-institution Italian study of 307 patients, lymphovascular invasion correlated with
loco-regional recurrence (p=0.001).35

Treatment
Because of the rarity of TC, there is insufficient data to determine the extent of
treatment necessary for this uncommon lesion. It is currently treated as a favorable,
early-stage breast cancer.

Systemic Therapy
Due to the rarity of the disease, the role of systemic chemotherapy in the
treatment of TC has not been firmly established. Though one study by Kitchen, et al. of
85 cases reported an 85% decrease in risk of death for patients receiving more than one
course of chemotherapy,33 another larger study by Diab et al. reported that of 277
patients, chemotherapy did not correlate with disease-free survival (p = 0.73).36
Consequently, the current National Comprehensive Cancer Network (NCCN) only
recommends the use of chemotherapy for ER- and PR-negative tubular lesions greater
than three centimeters in size or with positive regional nodal metastasis, which is a higher
threshold than that prescribed for invasive ductal lesions.37
Likewise, the role of endocrine therapy is equally uncertain. Despite the high
percentage of ER-positivity in tubular lesions, most studies do not demonstrate a survival
benefit or reduction in local failure. In particular, Diab et al., reported that of 277
patients, adjuvant endocrine therapy did not correlate with disease-free survival (p =
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0.16),

36

and in 48 ER-positive patients, Sullivan, et al. reported no decrease in risk of

local failure in 24 patients receiving tamoxifen.38 Therefore, the NCCN also advocates
for a higher threshold for the usage of tamoxifen than is prescribed for IDC. 37

Breast Conservation Therapy
As an early stage breast cancer, cases of TC are typically eligible for breast
conservation therapy (BCT), which is defined as a wide local excision of the tumor with
negative margins—accomplished with either lumpectomy, segmental mastectomy, or
excisional or incisional biopsy—combined with post-operative radiation therapy. But
prior to discussing BCT as it pertains to TC, an introduction to this relatively modern
approach is appropriate.
Though surgery remains integral to the management of patients with early-stage
breast cancer, the efficacy of post-operative radiotherapy introduced the notion of
providing select patients with a less aggressive alternative to mastectomy. Now after
numerous randomized control trials worldwide, the clinical equivalency of mastectomy
and BCT has been firmly established with regards to survival. In particular, two
landmark trials by Fisher, et al. and Veronesi, et al., randomizing patients to either breast
conserving surgery plus radiation versus mastectomy now have 20 years of follow up
data and have demonstrated the long-term DFS and OS rates to be equivalent in both
mastectomy and BCT cohorts. 1,2
In the Veronesi trial, the rate of death from all causes was 41.7% in the breast
conservation arm and 41.2% in the mastectomy arm (p = 1.0) at 20 years; the rates of
breast-cancer related death was 26.1% in the BCT arm and 24.3% in the mastectomy arm
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(p = 0.8). However, 30 women in the BCT cohort had an ipsilateral breast recurrence, in
contrast to 8 women in the mastectomy cohort (p <0.001), which provides a crude local
recurrence rate of 8.8% vs. 2.3%. However, there were no significant differences in rates
of contralateral breast carcinomas, distant metastases, or second primary cancers.
The National Surgical Adjuvant Breast and Bowel Project (NSABP) trial
conducted by Fisher et al. reported similar results to the Veronesi trial at 20 years, with
no significant differences observed with respect to disease-free survival, distant-diseasefree survival, or overall survival among patients randomized to BCT or mastectomy. In
addition, the hazard ratio for death among the BCT cohort, as compared with the
mastectomy cohort, was 0.97 (95 percent confidence interval, 0.83 to 1.14; P=0.74).
Therefore despite an increase in local failure rate, BCT has largely been established as
the treatment of choice for early stage breast cancers in regards to survival and cosmesis.
Unfortunately, rare breast cancer subtypes lack sufficient patients to conduct large
single-institution studies or randomized trials to determine the adequacy of BCT in their
treatment. However, studies by Vo, et al.,39 Weiss, et al.,40 and Thurman, et al.41
evaluated the outcomes of BCT for these uncommon subtypes in comparison to those of
IDC. In the study by Vo, et al., 1,643 patients formed the study population and consisted
of 61 cases of mucinous carcinomas, 37 cases of medullary carcinomas, 60 cases of TC,
and 1,485 cases of IDC. Amongst the groups, no statistically significant differences
were found in the local failure rate after a 10.6-year median follow-up, suggesting the
adequacy of BCT in their treatment. Of note, patients with TC had better 5- and 10-year
OS rates (p = .013) than the three other histologies. A study by Thurman, et al. of 20
cases of mucinous carcinoma, 27 cases of medullary, 28 cases of TC, and 1055 cases of
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IDC found similar results. After a 10 year follow-up period, a lower long-term rate of
DFS was observed in the IDC cohort, though this was not significantly different than that
of the other subtypes. A third study by Weiss, et al. comparing the same subtypes
reported similar results.40

Benefit of Radiation
The NSABP trial described above also featured a third cohort of women treated
with lumpectomy alone, which demonstrated the utility of radiotherapy. These women
suffered a cumulative incidence of ipsilateral breast recurrence of 39.2%, as compared
with 14.3% in women undergoing lumpectomy and post-operative irradiation at 20 year
follow-up (p < 0.001). The hazard ratio for death among the cohort receiving
lumpectomy alone, as compared with the mastectomy cohort, was 1.05 (95 percent
confidence interval, 0.90 to 1.23; P=0.51). Treatment by lumpectomy alone has been
demonstrated in numerous randomized trials to be associated with a three-fold increase in
local failure (Table 9).42-45 Though individual trials did not report differences in
survival, two recent metanalyses report a small, but statistically significant compromise
in survival of 5.3% and 8.6% by omission of radiation.42,46,47
Table 9. Randomized Trials of Breast-Conserving Therapy
With or Without Radiation
Rates of Local Relapse
Study

n

Follow-up

Radiotherapy

No Radiotherapy

Fisher et al.43

930

10 years

12.4%

40.9%

Liljegren et al.44

381

10 years

8.5%

24%

20

Veronesi et al.2

567

10 years

5.83%

23.5%

Clarke et al.47

837

3 years

5.5%

25.7%

Winzer et al.45

347

5.9 years

3.2%

27.8%

Table taken from Haffty B, Wilson, LD. Handbook of Radiation Oncology: Basic Principles and Clinical
Protocols. First ed: Jones and Bartlett Publishers, 2008:797.

Just as the adequacy of BCT in the treatment of TC has not been established, few
have addressed the precise role of radiation in the treatment of TC. A study by Leonard,
et al. of 44 patients with pure TC treated only by wide local excision reported a crude
local failure rate of 96% (2/44), 5- and 10-year local control rates of 100% and 87%, and
actuarial 5- and 10-year OS and DFS rates of 80% and 52%, and 100% and 91%.48 It
should be noted, however, that the patients in this study had lesions of pure tubular
histology and a median tumor size of only 6.5mm (range 2-30 mm). Further, the median
age was 67 years (range 40-96 years). Therefore, this retrospective study suggests that
breast irradiation might be omitted after conservative surgery in older patients with small
TC.
However, a literature review by Sullivan, et al. suggests that radiation may still
provide a benefit in local control to patients with TC.
Table 10. Literature Review of Conservatively Treated
Cases of Tubular Carcinoma
Conservative surgery

Conservative surgery

Without Radiotherapy

With Radiotherapy

Cases with

Total

Cases

Total

local failure

cases

with local

cases

Follow-up

failure

21

Tobon et al.49

0

2

0

1

23-month mean

Carstens12

2

5

-

-

24-month mean

Oberman et

2

2

-

-

67-month mean

Peters et al.13

0

1

0

2

74-month mean

Deos et al.6

3

8

-

-

144-month mean

McDivitt8

1

12

0

3

36-month mean

Weiss et al.40

-

-

2

18

61-month median

Winchester et

0

5

0

16

58-month median

Schnitt et al.50

0

7

-

-

56-month median

Haffty et al.51

-

-

0

21

113-month median

Bradford et

0

17

0

21

48-month median

0

5

0

22

144-month median

2

6

0

23

34.5-month median

Cabral et al.17

1

21

0

13

58-month mean

Thurman et

-

-

2

28

120-month

al.18

al.16

al.52
Kitchen et
al.33
Holland et
al.27

al.41

minimum

Livi et al.35

2

52

8

218

101-month median

Sullivan et

0

13

3

49

93-month median

22

al.38
Total

13

156
8.3%

15

435
3.4%

Table from Sullivan T, Raad RA, Goldberg S, Assaad SI, Gadd M, Smith BL, Powell SN, Taghian AG.
Tubular carcinoma of the breast: a retrospective analysis and review of the literature. Breast Cancer
Research and Treatment. 93: 199-205, 2005.

Future of Breast Conservation Therapy
Two recent randomized trials have questioned the need for radiation therapy in
elderly women. A study by Hughes, et al. randomized patients over 70 years of age with
early-stage, node-negative, ER-positive breast cancer to either radiotherapy and
tamoxifen or tamoxifen alone.53 At five years, radiotherapy significantly lowered local
failure rates, when compared to the tamoxifen alone group (1% vs. 4%, p <0.001), but
there were no significant differences between the two groups with regard to the rates of
mastectomy for local recurrence, distant metastases, or overall survival (87% vs. 86%, p
= 0.94). In comparison, a study by Fyles, et al. of patients greater than 50 years of age
also demonstrated no significant differences in the rates of distant metastasis or overall
survival.54 However, the five-year disease-free survival rates (84% vs. 91%; p = 0.004)
and local relapse rates (7.7% vs. 0.6%, p <0.001) favored the radiation cohort. Longer
follow-up data for both studies is awaited.
Another potential development in BCT is the use of partial breast irradiation
following lumpectomy. For patients with low-risk disease, this approach allows for less
radiation to be delivered over a shorter course to a restricted breast volume. The
radiation can be delivered utilizing a variety of techniques including multiplane
interstitial catheters, Mammosite-brand balloon, or external beam conformal therapy.
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The efficacy and safety of partial breast irradiation is currently being studied in an
ongoing randomized trial, as compared to traditional BCT.

Breast Conservation Therapy in the Treatment of Tubular Carcinoma
Despite its benign histopathologic characteristics, however, TC has been observed
to have features which are potentially incompatible with a conservative approach to local
therapy. In particular, numerous studies have documented an increased frequency of
multi-centricity and synchronous or metachronous contralateral disease.16,26,27 These
characteristics may indicate an increased risk of local recurrence or second primary and
demand a more aggressive means of local therapy.
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STATEMENT OF PURPOSE
The purpose of our investigation was to identify patients with TC treated with
BCT at our institution. Like studies by Vo, et al.39 Weiss, et al.,40 and Thurman, et al.41
discussed above, we aim to elucidate the role of BCT for the treatment of TC by
comparing the clinical-pathologic features and long-term outcomes of patients with TC to
those of our large cohort of patients with IDC. Our hypothesis is that patients with TC
will have more favorable pre-treatment clinical-pathologic characteristics than those of
the IDC cohort and that clinical outcomes will be comparable between the two subtypes
following BCT.
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MATERIALS AND METHODS
Prior to initiating this study, institutional review board (IRB) approval was
obtained by Dr. Meena Moran to review hospital charts and pathology slides. From
tumor registry data, a list of all tubular breast cancer cases treated at the facilities of Yale
University School of Medicine was compiled by Gene-Fu Liu (GFL) with the aid of the
Yale Tumor Registry and was referenced against a list compiled by Drs. Bruce G. Haffty
(BGH) and Meena S. Moran (MSM). To identify which of these TC patients were treated
with BCT, medical chart reviews were conducted by GFL.
Our study cohort was therefore comprised of Stage I/II TC patients who all
received conservative surgery and radiation therapy. Patients with TC who had pathology
slides available for review underwent central pathology review. Slides were read by a
single breast pathologist, Dr. Qifeng Yang (QY), at the Pathology Department of Yale
New Haven Hospital. Tubular histology was designated to any cases that had greater than
75% tubular histology as designated by the Stanford Surgical Pathology Criteria.7
Patients with lesions comprised of less than 75% tubular histology were excluded from
the TC cohort; as stated above, such lesions have been demonstrated to exhibit a natural
history similar to that of IDC.12,13 Our comparison cohort consisted of 2238 patients with
Stage I or II invasive ductal histology treated with BCT, identified from our departmental
breast cancer database, which was compiled by BGH and MSM. Chart reviews from the
Departments of Therapeutic Radiology of Yale University were conducted by GFL to
gather clinical, pathologic and outcomes data on the tubular cohort, and the relevant
information was entered into our database for analysis. Data on the invasive ductal
cohort was collected previously by BGH and MSM.
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All patients analyzed in this study were treated with conservative surgery and
radiation therapy. Conservative surgery consisted of excisional biopsy, lumpectomy,
quadrantectomy or partial mastectomy, with or without re-excision, to attempt to achieve
negative surgical margins. Whole breast RT was delivered to a median dose of 48 Gy
using standard tangential techniques, and all patients received a conedown/boost field.
The boost was delivered in the majority of patients using an en-face electron field which
was designed to encompass the surgical scar plus a generous margin. The total median
dose (including cone-down) for both cohorts was 64 Gy. Regional nodal radiation was
delivered as previously described.55 Systemic therapy was delivered at the discretion of
the treating oncologist. Patients who received neoadjuvant chemotherapy were excluded
from analysis. All clinical and pathologic variables of the 2 cohorts were statistically
analyzed using SAS, Version 9.1 (SAS Institute, Cary, NC). All tests of statistical
significance were 2-sided and significance was defined as a p value less than 0.05.
Bivariate analysis for the association between co-variables and histology were performed
using chi2 analysis and the Fisher’s exact test. Outcome parameters were defined as
follows: breast recurrence free survival: time of diagnosis to time of local failure within
breast; nodal recurrence free survival: time of diagnosis to time of relapse in the axilla,
supraclavicular fossa or internal mammary nodes; distant metastasis free survival: time
of diagnosis to disease failure outside of the local-regional area.

All events were

calculated using standard life table methods and the differences were compared using
Cox regression models.
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RESULTS
The median follow-up for the two cohorts was 7 years. Table 11 stratifies the pretreatment characteristics of patients by subtype.
Table 11. Pre-Treatment Characteristics by Subtype
Stage I/II Invasive Ductal
Tubular Carcinoma

P value

55.8 yrs (range 20-90)

55.6 yrs (range 35-84)

NS

954/1891 (50%)

51/64 (80%)

<0.0001

T1 Disease

1445/1798 (80.37%)

65/67% (97.01%)

0.0004

N0 Disease

938/1273 (73.68%)

40/42(95.24%)

0.0016

ER positivity

943/1530 (61.67%)

42/47 (89.36%)

0.0001

PR positivity

719/1391 (51.69%)

35/43 (81.40%)

0.0001

123/422 (29.15%)

3/27 (11.11%)

0.043

665/1837 (36.20%)

29/64 (45.31%)

NS (0.1366)

127/1412 (8.99%)

1/49 (2.04%)

NS (0.1207)

669/2068 (32.35%)

27/66 (40.91%)

NS (0.1443)

571/2075 (27.52%)

6/70 (8.57%)

0.0004

Carcinoma
Age
Detected by
Mammography

HER-2
positivity
Family history
Positive
margins
Adjuvant
Hormonal
Therapy
Adjuvant
Chemotherapy
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Abbreviations: NS = not significant

Central Pathology Review
Forty-seven patients had pathology slides available for review.

Of these, 77%

(36/47) were confirmed as being of the TC subtype. 11 patients were deemed to have
<75% tubular histology and were subsequently not included in the clinical-pathologic and
outcomes analysis.

Patient characteristics
The average age at presentation was 55.6 years (range 35-84 years) for TC and 55.8
years (range 20-90) for IDC, respectively (p=NS). A significantly greater percentage of
TC lesions were detected mammographically (80% vs. 50%; p<0.0001). Of the 64 TC
patients with known family history, 29 (45%) have a family history of breast cancer
compared with 36% of the IDC cohort (p=0.14).

Tumor characteristics
At presentation, the TC cohort was associated with a greater percentage of pathologic
T1 disease (97% vs. 80%; p=0.0007). Furthermore, of the 43 TC patients with axillary
staging (15 by sentinel node biopsy and 25 by axillary node dissection), nodal spread was
detected in only 2 cases (5%), which is significantly less than the 26% (335/1272) of IDC
patients with nodal metastases (p = 0.0016). TC cases also exhibited increased estrogen
(ER) and progesterone receptor (PR) expression in comparison to IDC lesions, 89% vs.
62% (p=0.0001) and 81% vs. 52% (p=0.0001), respectively. HER-2 status was reported
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as positive in 11% of the TC cases and 29% of IDC cases (p = 0.04)

Adjuvant systemic therapy
Following definitive local therapy, adjuvant hormonal therapy was administered in
approximately equal proportions of TC and IDC cases (41% vs. 32%; p = 0.14).
Significantly fewer TC patients received adjuvant chemotherapy, 9% versus 28% (p =
0.0004).

Clinical outcomes
Figure 1 shows survival curves by outcome. At ten years, overall survival (90% vs.
80%; p=0.033), cause-specific survival (98 vs. 86%; p=0.011), disease-free survival (99%
vs. 82%; p=0.003) all favored the TC cohort.

Though there was a trend towards

improved breast relapse-free survival for the TC cohort than IDC (95% vs. 87%), this
difference did not achieve statistical significance (p=0.062). There was no difference in
nodal relapse-free survival (100% vs. 97%; p=0.216) and contralateral breast relapse-free
survival (85% vs. 87%; p=0.868) between the 2 cohorts.
Table 12. Clinical Outcomes by Subtype
Stage I/II Invasive
Tubular Carcinoma

P value

80%

90%

0.033

86%

98%

0.011

Ductal Carcinoma
10-year
Overall Survival
10-year CauseSpecific Survival
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10-year Ipsilateral
Breast Relapse-

87%

95%

NS (0.062)

82%

99%

0.003

97%

100%

NS (0.216)

87%

85%

NS (0.868)

Free Survival
10-year DiseaseFree Survival
10-year Nodal
Relapse-Free
Survival
10-year
Contralateral
Breast-Relapse
Free Survival
Abbreviations: NS = not significant
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DISCUSSION
This study compares the clinical-pathologic features and long-term outcomes of a
relatively large cohort of patients with TC treated with BCT with those of a similarly
treated cohort of patients with IDC. Overall, prognostic features and clinical outcomes
parameters favored the TC cohort. Specifically, pathologic T and N stages and rates of
hormone receptor negativity or HER-2 over-expression were higher in the IDC cohort. In
regards to outcomes, cause-specific, disease-free, and overall survival also favored
patients with TC over those with IDC. The excellent outcomes of our TC cohort support
the adequacy of a conservative approach to the treatment of TC.
Though these results may be expected from a subtype once termed the “welldifferentiated carcinoma of the breast,”26 there have been concerns over the use of BCT
in regards to two observed features of TC. First, Lagios et al. reported a 56% rate of
multicentricity in 17 cases of TC,26 which may suggest a potential for increased risk of
local recurrence with a conservative therapy. Second, numerous studies have noted an
increased incidence of contralateral cancer before, during, or after the initial diagnosis of
TC,

with

a

review

of

the

literature

revealing

a

14%

incidence

of

metachronous/synchronous contralateral disease (Table 13).
Table 13. Incidence of Contralateral Invasive Disease
in Patients with Tubular Carcinoma
Study

No. of Patients

No. with Contralateral
Carcinoma (%)

Carstens et al.11

42

5 (12%)

32

Cooper et al.34

12

2 (17%)

Oberman et al.18

25

3 (12%)

Lagios et al.26

16

6 (38%)

Peters et al.13

36

3 (8%)

Deos et al.6

90

9 (10%)

Winchester et al.16

50

13 (26%)

Taylor et al.56

33

6 (18%)

Thurman et al.41

38

3 (8%)

Günhan-Bilgen et al. 57

32

4 (13%)

Liu et al. (current study)

71

11 (15%)

TOTAL

445

65 (15%)

This figure is slightly higher than the 2-11% incidence reported for all subtypes58 and
may suggest a propensity towards developing a second primary lesion. The basis of
increased contralateral disease in TC is unknown, though it had been once been
postulated to arise from the subtype’s high frequency of intraductal disease. However,
this concept was not supported by a subset analysis by Winchester et al., which did not
show a correlation between intraductal disease and contralateral disease in patients with
TC.16 Also of note, our study does not demonstrate that patients with TC are more likely
than those with IDC to have had or develop metachronous contralateral breast cancer.
Our results are consistent with the existing literature addressing TC. The 5-year
99% DFS and 96% OS exhibited by our TC cohort agree with the clinical outcomes of a
larger multi-institutional study comparing TC with IDC by Diab et al., which included
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cases treated with mastectomy,36 as well as with three smaller single-institution studies
comparing TC to other histologies treated exclusively with BCT by Vo et al39, Weiss, et
al.,40 and Thurman et al. (Table 14).41 Of note, in our review of the literature, this is the
largest known single-institution study comparing cases of TC to IDC treated exclusively
with BCT.
Table 14. Subsets of Patients with Tubular Carcinoma
Treated with BCT in Previous Studies
Study

Local Recurrence Rate

Follow-up

Winchester, et al. 16

0/16 (0%)

58 months median

Sullivan, et al.38

3/49 (6%)

90.5 months median

Livi, et al.35

8/218 (4%)

100.8 months median

Cabral, et al.17

0/13 (0%)

55 months mean

Thurman, et al. 41

2/28 (7%)

10 years, minimum

Vo, et al.39

8/60 (13%)

10.6 years, median

Liu, et al. (current study)

4/70 (6%)

84 months median

Total

15/366 (4%)

Abbreviations: BCT = breast conservation therapy

However, this study has several weaknesses which merit discussion. Given the time
span of nearly 3 decades in which these patients were treated, and the fact that a
significant portion of the patients had surgery elsewhere and were subsequently referred
to our institution for radiation treatment, the availability of slides for central pathology
review was limited. Furthermore, of the slides available for review, nearly one-quarter
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were re-classified by our pathologist as a different histologic subtype due to the stringent
criteria applied. Of note, there was no stratification of pure versus mixed TC (defined in
the literature as consisting of greater than 90% and 75% tubular histology, respectively)
as previous studies have indicated similar outcomes for both histologies.13,17,59
Another weakness of our study was the inability to perform multivariate analysis due
to the relatively small number of patients in the TC cohort, which may also have
underpowered the study to detect statistically significant differences. Specifically, it is
possible that the breast and nodal relapse free survival for the TC may indeed be better
than for IDC, but our study may have been limited in numbers of patients to detect this
difference as significant. Furthermore, this may have compromised our assessment of
conventional prognostic and predictive features, e.g., nodal positivity or hormone
receptor status. An important question that our study did not address was how cases of
TC fare with BCT versus mastectomy, however, our breast database consists of patients
treated with only breast conservation, and therefore we are unable to address this
question. Finally, the retrospective nature of this study introduces significant bias, with
respect to patient selection and intrinsic, retrospective data collection.
Though not directly compared between our two cohorts, an interesting phenomena
described in the literature is the high percentage of patients with positive family histories
in patients with tubular histology of breast cancer. In our study, of the 58 cases in which
family history was documented, 28 (47%) reported a positive history, which is consistent
with studies by Lagios et al.26 and Holland et al.27 Though the number of TC cases
reporting positive histories was not significantly different than that of our IDC patients
(36%), it is important to note that a large number of patients (22%) from the IDC cohort
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did not have family history data available for analysis, which potentially confounds this
analysis.
In conclusion, patients with TC of the breast treated with BCT have excellent longterm outcomes that are comparable to, if not more favorable than, those of similarly
treated patients with IDC. These findings support the routine utilization of BCT for the
management of this rare histologic subtype.
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Figure 1. Survival curves for Tubular Carcinoma versus Invasive Ductal Carcinoma.
Solid Line: Invasive Ductal Carcinoma, Broken Line: Tubular Carcinoma
a.) Overall Survival
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